Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of AC-262536 and Ligandrol (LGD-4033) — mechanism, side effects, legal status, and pricing.
AC-262536 is a non-peptide nonsteroidal selective androgen receptor modulator (SARM) with an azabicyclooctane naphthalene-carbonitrile structure. It acts as a partial AR agonist, showing tissue-selective anabolic effects in preclinical models. No human trials have been conducted, and it is not FDA-approved. SARMs are prohibited in athletic competition under WADA category S1.2.
Ligandrol (LGD-4033) is a nonsteroidal selective androgen receptor modulator (SARM) of the substituted pyrrolidinyl-benzonitrile chemotype. It has been tested in Phase 1 and Phase 2 clinical trials for muscle wasting and hip-fracture recovery but has no FDA-approved medical use anywhere. LGD-4033 is prohibited at all times (in- and out-of-competition) under WADA Prohibited List section S1.2, “Other Anabolic Agents” (SARMs class). It is sold online as an unregulated “research chemical” of unverified purity and dose.
AC-262536
Ligandrol (LGD-4033)
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
AC-262536
Ligandrol (LGD-4033)
No pricing data yet.
Check Ligandrol (LGD-4033) prices →COA corpus from Disclosed Labs — independently tested batches only.
AC-262536
No COA data yet.
Submit testing data →Ligandrol (LGD-4033)
2
COAs
99.4%
Avg purity
1
Labs
No human data exist. All pharmacology derives from a single 2008 preclinical publication. In castrated male rats dosed chronically for two weeks, AC-262536 significantly increased levator ani muscle growth and suppressed elevated luteinizing hormone, while producing only weak effects on prostate and seminal vesicle weight compared to testosterone. The compound has also been included in validated analytical panels for SARM residue surveillance in bovine muscle tissue, reflecting its presence in food-safety monitoring rather than therapeutic development.
Human data are limited to investigational trials and case reports; no approved medical use exists. A Phase 1 randomized, double-blind, placebo-controlled trial (Basaria et al. 2013, N=76 healthy men aged 21–50) tested 0.1, 0.3, and 1.0 mg/day for 21 days and found dose-dependent increases in lean body mass, with dose-dependent suppression of testosterone, SHBG, HDL cholesterol, and triglycerides that normalized after stopping. A Phase 2 trial (VK5211, N=108 hip-fracture-recovery patients, 0.5–2.0 mg/day for 12 weeks) reported via press release placebo-adjusted lean-mass increases of 4.8–9.1% with no drug-related serious adverse events; this result has not been peer-reviewed. Published case reports document severe cholestatic hepatitis (total bilirubin 35.0 mg/dL) in a 32-year-old male after ∼10 mg/day for ∼2 weeks—a dose 10–100× higher than trial doses—and marked testosterone suppression (−62.3%), elevated liver enzymes (ALT +205%, AST +96%), and adverse lipid changes in a 25-year-old male using 10 mg/day for 5 weeks; both cases involved unsupervised gray-market product. In ovariectomized rats (osteoporosis model), oral LGD-4033 at 0.04–4 mg/kg/day for 5 weeks increased muscle capillary density at all doses, elevated oxidative enzymes at intermediate doses, and increased muscle fiber cross-sectional area at the highest dose, but also increased intramuscular fat and uterine weight at 4 mg/kg, indicating loss of tissue selectivity at high exposure.
AC-262536 and Ligandrol (LGD-4033) are both in the Performance category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Key references
Disclosed Labs